QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$58.53
-0.19 (-0.32 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$57.04
Now: $58.53
$58.89
50-Day Range
$58.72
MA: $63.00
$66.34
52-Week Range
$57.04
Now: $58.53
$85.97
Volume12.04 million shs
Average Volume14.67 million shs
Market Capitalization$73.38 billion
P/E RatioN/A
Dividend Yield4.63%
Beta0.55
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Read More
Gilead Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.73 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Employees11,800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.05 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Outstanding Shares1,253,724,000
Market Cap$73.38 billion
Next Earnings Date2/2/2021 (Estimated)
OptionableOptionable
$58.53
-0.19 (-0.32 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by COVID-19 (Coronavirus)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GILD shares have decreased by 20.6% and is now trading at $58.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 2 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Gilead Sciences
.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported $2.11 EPS for the quarter, beating analysts' consensus estimates of $1.90 by $0.21. Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Wednesday, October 28th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.68 per share on Wednesday, December 30th. This represents a $2.72 dividend on an annualized basis and a yield of 4.65%.
View Gilead Sciences' dividend history
.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences updated its FY20 earnings guidance on Wednesday, October, 28th. The company provided earnings per share (EPS) guidance of $6.25-6.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.87. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

27 brokers have issued twelve-month price objectives for Gilead Sciences' stock. Their forecasts range from $61.00 to $105.00. On average, they expect Gilead Sciences' share price to reach $76.62 in the next year. This suggests a possible upside of 30.9% from the stock's current price.
View analysts' price targets for Gilead Sciences
.

Has Gilead Sciences been receiving favorable news coverage?

News headlines about GILD stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gilead Sciences earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
View the latest news about Gilead Sciences
.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 56, Pay $10.86M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 50, Pay $6.91M)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 52, Pay $2.14M)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 50, Pay $2.55M)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 57, Pay $1.12M)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 58)
  • Ms. Jyoti K. Mehra, Exec. VP of HR
  • Dr. William A. Lee, Exec. VP of Research (Age 65)
  • Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 66)
  • Dr. Diana Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 49)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include LSV Asset Management (0.37%), Railway Pension Investments Ltd (0.16%), Robeco Institutional Asset Management B.V. (0.16%), Candriam Luxembourg S.C.A. (0.15%), DNB Asset Management AS (0.15%) and DekaBank Deutsche Girozentrale (0.13%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Resources Investment Advisors LLC., Standard Life Aberdeen plc, Cambridge Investment Research Advisors Inc., Transform Wealth LLC, Nisa Investment Advisors LLC, Usca Ria LLC, and Redpoint Investment Management Pty Ltd. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, and Olsen Per Wold.
View insider buying and selling activity for Gilead Sciences
.

Which major investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, DekaBank Deutsche Girozentrale, Robeco Institutional Asset Management B.V., Envestnet Asset Management Inc., State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., PGGM Investments, and Capital Investment Advisors LLC.
View insider buying and selling activity for Gilead Sciences
.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $58.53.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $73.38 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.